Vitruvias Therapeutics and Sinotherapeutics team up to launch bioequivalent Rythmol SR in US
Vitruvias Therapeutics, a US-based finished-dose generic drug manufacturer, has announced the US launch of a bioequivalent, FDA-approved version of the antiarrhythmic drug Rythmol SR, in ... Read More